Bupivacaine hydrochloride monohydrate, 98+%
Bupivacaine hydrochloride monohydrate, 98+%
Bupivacaine hydrochloride monohydrate, 98+%
Thermo Scientific Chemicals

Bupivacaine hydrochloride monohydrate, 98+%

Inhibits TREK-1 channels and depolarizes the cell membrane | CAS: 73360-54-0 | C18H31ClN2O2 | 342.908 g/mol
Have Questions?
Modifier l'affichagebuttonViewtableView
Quantité:
1 g
5 g
25 g
Référence J62835.06
également connu sous le numéro J62835-06
Prix (EUR)
191,00
Each
Quantité:
5 g
Grand volume ou format personnalisé
Prix (EUR)
191,00
Each
Identifiants chimiques
CAS73360-54-0
IUPAC Name1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrate hydrochloride
Molecular FormulaC18H31ClN2O2
InChI KeyHUCIWBPMHXGLFM-UHFFFAOYNA-N
SMILESO.Cl.CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C
Voir plus
Appearance (Color)White
Assay (HPLC)>98.0%
Impurity contentHeavy metals: 0.1% max.
Water Content (Karl Fischer Titration)4.0 - 6.0%
FormPowder
It is employed as Na+ channel blocker, local anesthetic and cAMP production inhibitor. It acts as a surfactant molecule possessing both hydrophilic and lipophilic properties, adrenergic antagonist, EC 3.1.1.8 (cholinesterase) inhibitor and EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor.

This Thermo Scientific Chemicals brand product was originally part of the Alfa Aesar product portfolio. Some documentation and label information may refer to the legacy brand. The original Alfa Aesar product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.

Applications
It is employed as Na+ channel blocker, local anesthetic and cAMP production inhibitor. It acts as a surfactant molecule possessing both hydrophilic and lipophilic properties, adrenergic antagonist, EC 3.1.1.8 (cholinesterase) inhibitor and EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor.

Solubility
Soluble in water to 50 mM, in DMSO to 100 mM and in ethanol to 100 mM.

Notes
Store away from oxidizing agents. Keep the container tightly closed and place it in a cool, dry and well ventilated condition.
RUO – Research Use Only

General References:

  1. Viscusi ER, et al. The safety of liposome bupivacaine, a novel local analgesic formulation.Clinical pharmacology and therapeutics.,2014,30(2), 102-110.
  2. Hu D, et al. Pharmacokinetic profile of liposome bupivacaine injection following a single administration at the surgical site.Clinical drug investigation.,2013,33(2), 109-115.